Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Drug Resistance

  Free Subscription

Articles published in J Virol

Retrieve available abstracts of 36 articles:
HTML format

Single Articles

    April 2021
  1. MORI K, Ohniwa RL, Takizawa N, Naito T, et al
    Development of a Genetically Stable Live Attenuated Influenza Vaccine Strain using an Engineered High-Fidelity Viral Polymerase.
    J Virol. 2021 Apr 7. pii: JVI.00493-21. doi: 10.1128/JVI.00493.
    PubMed     Abstract available

    October 2020
  2. LEE J, Parvathareddy J, Yang D, Bansal S, et al
    Emergence and Magnitude of ML336 Resistance in Venezuelan Equine Encephalitis Virus Depend on the Microenvironment.
    J Virol. 2020;94.
    PubMed     Abstract available

  3. JEONG JH, Choi WS, Antigua KJC, Choi YK, et al
    In vitro profiling of laninamivir-resistant substitutions in N3 to N9 avian influenza neuraminidase subtypes and their association with in vivo susceptibility.
    J Virol. 2020 Oct 14. pii: JVI.01679-20. doi: 10.1128/JVI.01679.
    PubMed     Abstract available

    September 2020
  4. PINKERT S, Kopp A, Bruckner V, Fechner H, et al
    Single-Point Mutations within the Coxsackie B Virus Receptor-Binding Site Promote Resistance against Soluble Virus Receptor Traps.
    J Virol. 2020;94.
    PubMed     Abstract available

    August 2020
  5. ST BERNARD L, Abolade J, Mohri H, Markowitz M, et al
    Drug-resistance mutation frequency of SGA-derived HIV-1 polymerase genomes in the CSF and plasma of HIV-1-infected individuals under non-suppressive therapy.
    J Virol. 2020 Aug 5. pii: JVI.01824-19. doi: 10.1128/JVI.01824.
    PubMed     Abstract available

    July 2020
  6. KEMPF BJ, Watkins CL, Peersen OB, Barton DJ, et al
    An Extended Primer Grip of Picornavirus Polymerase Facilitates Sexual RNA Replication Mechanisms.
    J Virol. 2020;94.
    PubMed     Abstract available

    May 2020
  7. MEDIOUNI S, Jablonski JA, Tsuda S, Barsamian A, et al
    Oregano oil and its principal component carvacrol inhibit HIV-1 fusion into target cells.
    J Virol. 2020 May 27. pii: JVI.00147-20. doi: 10.1128/JVI.00147.
    PubMed     Abstract available

    January 2020
  8. MELODY K, Roy CN, Kline C, Cottrell ML, et al
    Long-acting rilpivirine (RPV LA) pre-exposure prophylaxis does not inhibit vaginal transmission of RPV-resistant HIV-1 nor select for high frequency drug resistance in humanized mice.
    J Virol. 2020 Jan 22. pii: JVI.01912-19. doi: 10.1128/JVI.01912.
    PubMed     Abstract available

    December 2019
  9. HERNANDEZ MM, Fahrny A, Jayaprakash A, Gers-Huber G, et al
    Impact of suboptimal APOBEC3G neutralization on the emergence of HIV drug resistance in humanized mice.
    J Virol. 2019 Dec 4. pii: JVI.01543-19. doi: 10.1128/JVI.01543.
    PubMed     Abstract available

    August 2019
  10. WENSEL D, Sun Y, Davis J, Li Z, et al
    GSK3732394: A multi-specific inhibitor of HIV entry.
    J Virol. 2019 Aug 2. pii: JVI.00907-19. doi: 10.1128/JVI.00907.
    PubMed     Abstract available

    March 2019
  11. ZHUANG M, Vassell R, Yuan C, Keller PW, et al
    Mutations that increase the stability of the post-fusion gp41 conformation of the HIV-1 envelope glycoprotein are selected by both an X4 and R5 HIV-1 virus to escape fusion inhibitors corresponding to heptad repeat 1 of gp41, but the gp120 adaptive mu
    J Virol. 2019 Mar 20. pii: JVI.00142-19. doi: 10.1128/JVI.00142.
    PubMed     Abstract available

  12. BOYER PL, Melody K, Smith SJ, Dunn LL, et al
    Two Co-Selected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Non-nucleoside RT Inhibitors and Nucleoside Analogs.
    J Virol. 2019 Mar 20. pii: JVI.00224-19. doi: 10.1128/JVI.00224.
    PubMed     Abstract available

  13. ZHU Y, Chong H, Yu D, Guo Y, et al
    Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    J Virol. 2019 Mar 13. pii: JVI.02312-18. doi: 10.1128/JVI.02312.
    PubMed     Abstract available

  14. SAHUC ME, Sahli R, Riviere C, Pene V, et al
    Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus Is a New Inhibitor of Hepatitis C Virus RNA Replication.
    J Virol. 2019 Mar 6. pii: JVI.02009-18. doi: 10.1128/JVI.02009.
    PubMed     Abstract available

    February 2019
  15. WU E, Du Y, Gao X, Zhang J, et al
    V1 and V2 Domains of HIV Envelope Contribute to CCR5 Antagonist Resistance.
    J Virol. 2019 Feb 20. pii: JVI.00050-19. doi: 10.1128/JVI.00050.
    PubMed     Abstract available

  16. YOSHIDA T, Shiraishi T, Hagiwara-Komoda Y, Komatsu K, et al
    The Plant Noncanonical Antiviral Resistance Protein JAX1 Inhibits Potexviral Replication by Targeting the Viral RNA-Dependent RNA Polymerase.
    J Virol. 2019;93.
    PubMed     Abstract available

    January 2019
  17. KLEINE-WEBER H, Elzayat MT, Wang L, Graham BS, et al
    Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization.
    J Virol. 2019;93.
    PubMed     Abstract available

    December 2018
  18. URANO E, Timilsina U, Kaplan JA, Ablan S, et al
    J Virol. 2018 Dec 19. pii: JVI.02017-18. doi: 10.1128/JVI.02017.
    PubMed     Abstract available

    October 2018
  19. VAN ROMPAY KK, Hassounah S, Keele BF, Lifson JD, et al
    Dolutegravir monotherapy of simian immunodeficiency virus-infected macaques selects for several patterns of resistance mutations with variable virological outcomes.
    J Virol. 2018 Oct 31. pii: JVI.01189-18. doi: 10.1128/JVI.01189.
    PubMed     Abstract available

  20. PRACHANRONARONG KL, Canale AS, Liu P, Somasundaran M, et al
    Mutations in influenza A virus neuraminidase and hemagglutinin confer resistance against a broadly neutralizing hemagglutinin stem antibody.
    J Virol. 2018 Oct 31. pii: JVI.01639-18. doi: 10.1128/JVI.01639.
    PubMed     Abstract available

    August 2018
  21. WANG P, Liu Y, Zhang G, Wang S, et al
    Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.
    J Virol. 2018;92.
    PubMed     Abstract available

  22. RUAN L, Hadden JA, Zlotnick A
    Assembly properties of Hepatitis B Virus core protein mutants correlate with their resistance to assembly-directed antivirals.
    J Virol. 2018 Aug 8. pii: JVI.01082-18. doi: 10.1128/JVI.01082.
    PubMed     Abstract available

    June 2018
  23. NEVOT M, Jordan-Paiz A, Martrus G, Andres C, et al
    HIV-1 Protease Evolvability is Affected by Synonymous Nucleotide Recoding.
    J Virol. 2018 Jun 6. pii: JVI.00777-18. doi: 10.1128/JVI.00777.
    PubMed     Abstract available

    January 2018
  24. WU X, Liu Z, Ding X, Yu D, et al
    Mechanism of HIV-1 Resistance to an Electronically Constrained alpha-Helical Peptide Membrane Fusion Inhibitor.
    J Virol. 2018 Jan 10. pii: JVI.02044-17. doi: 10.1128/JVI.02044.
    PubMed     Abstract available

    October 2017
  25. CHOI WS, Jeong JH, Kwon JJ, Ahn SJ, et al
    Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6 and N8 Neuraminidase Subtypes.
    J Virol. 2017 Oct 18. pii: JVI.01580-17. doi: 10.1128/JVI.01580.
    PubMed     Abstract available

    August 2017
  26. ANSTETT K, Brenner B, Mesplede T, Wainberg MA, et al
    HIV-1 resistance to dolutegravir is affected by cellular histone acetyltransferase activity.
    J Virol. 2017 Aug 23. pii: JVI.00912-17. doi: 10.1128/JVI.00912.
    PubMed     Abstract available

  27. CHAILLON A, Nakazawa M, Wertheim JO, Little SJ, et al
    No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men.
    J Virol. 2017 Aug 9. pii: JVI.00769-17. doi: 10.1128/JVI.00769.
    PubMed     Abstract available

  28. RAI DK, Diaz-San Segundo F, Campagnola G, Keith A, et al
    Attenuation of Foot-and-Mouth Disease Virus by Engineered Viral Polymerase Fidelity.
    J Virol. 2017;91.
    PubMed     Abstract available

    June 2017
  29. ABDELNABI R, Morais ATS, Leyssen P, Imbert I, et al
    Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.
    J Virol. 2017;91.
    PubMed     Abstract available

    February 2017
  30. WANG W, Zhou J, Halambage UD, Jurado KA, et al
    Inhibition of HIV-1 Maturation via Small Molecule Targeting of the Amino-Terminal Domain in the Viral Capsid Protein.
    J Virol. 2017 Feb 15. pii: JVI.02155-16. doi: 10.1128/JVI.02155.
    PubMed     Abstract available

    October 2016
  31. XIONG S, Borrego P, Ding X, Zhu Y, et al
    A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activities against HIV-1, HIV-2 and Simian Immunodeficiency Virus.
    J Virol. 2016 Oct 19. pii: JVI.01839.
    PubMed     Abstract available

    September 2016
  32. WU Y, Gao F, Qi J, Bi Y, et al
    Resistance to mutant group-2 influenza neuraminidases of an oseltamivir-zanamivir hybrid inhibitor.
    J Virol. 2016 Sep 21. pii: JVI.01703.
    PubMed     Abstract available

    July 2016
  33. VAUSSELIN T, Seron K, Lavie M, Mesalam AA, et al
    Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus.
    J Virol. 2016 Jul 13. pii: JVI.00404.
    PubMed     Abstract available

  34. MURGATROYD C, Pirrie L, Tran F, Smith TK, et al
    Structure-activity relationships of the Human Immunodeficiency Virus Type 1 maturation inhibitor PF-46396.
    J Virol. 2016 Jul 6. pii: JVI.01075.
    PubMed     Abstract available

    June 2016
  35. WEISSHAAR M, Cox R, Morehouse Z, Kyasa S, et al
    Identification and Characterization of Influenza Virus Entry Inhibitors Through Dual-Myxovirus High-Throughput Screening.
    J Virol. 2016 Jun 1. pii: JVI.00898.
    PubMed     Abstract available

  36. BETZ-STABLEIN BD, Topfer A, Littlejohn M, Yuen L, et al
    Single-molecule sequencing reveals complex genomic variation of hepatitis B virus during 15 years of chronic infection following liver transplantation.
    J Virol. 2016 Jun 1. pii: JVI.00243.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.